QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial

Intercept Pharmaceuticals (ICPT) Earnings Date, Estimates & Call Transcripts

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free ICPT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Stock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipSocial MediaSustainability
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

ICPT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ICPT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Intercept Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242$0.13$0.28$0.21 
Q2 20243($0.06)$0.65$0.34 
Q3 20241$0.69$0.69$0.69 
Q4 20241$0.63$0.63$0.63 
FY 20247$1.39$2.25$1.86 
Q1 20251$0.37$0.37$0.37 
Q2 20251$0.34$0.34$0.34 
Q3 20251$0.43$0.43$0.43 

Intercept Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/6/2023Q3 2023($0.27)($0.07)+$0.20($0.07)$88.02 million$88.79 million
8/2/2023Q2 2023($0.56)($0.14)+$0.42($0.14)$79.57 million$83.70 million    
4/27/2023Q1 2023($0.57)($0.77)($0.20)($0.77)$72.68 million$67.96 million    
3/2/2023Q4 2022($0.53)($0.42)+$0.11($0.34)$76.89 million$77.22 million
11/1/2022Q3 2022$5.11($3.04)($8.15)($13.88)$75.60 million$77.59 million
8/3/2022Q2 2022($0.53)($0.68)($0.15)($1.11)$94.85 million$100.40 million    
5/6/2022Q1 2022($0.89)($0.58)+$0.31($0.58)$90.86 million$88.58 million    
3/2/2022Q4 2021($1.26)($1.23)+$0.03($1.23)$91.89 million$92.40 million    
11/3/2021Q3 2021($1.00)($0.11)+$0.89($1.15)$83.04 million$92.80 million    
7/29/2021Q2 2021($1.24)($0.33)+$0.91($0.33)$82.64 million$96.58 million    
5/6/2021Q1 2021($1.53)($1.22)+$0.31($1.22)$81.17 million$81.66 million  

Intercept Pharmaceuticals Earnings - Frequently Asked Questions

How much revenue does Intercept Pharmaceuticals generate each year?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a recorded annual revenue of $285.71 million.

How much profit does Intercept Pharmaceuticals generate each year?

Intercept Pharmaceuticals (NASDAQ:ICPT) has a recorded net income of $221.82 million. ICPT has generated -$1.48 earnings per share over the last four quarters.

What is Intercept Pharmaceuticals's EPS forecast for next year?

Intercept Pharmaceuticals's earnings are expected to grow from ($1.04) per share to $1.93 per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:ICPT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media